40 stories found
Several executives from companies including Crowdstrike, CoreWeave, Acm Research, and Legalzoom sold millions of dollars in company stock, while a director at Nightfood Holdings made a minor purchase.
Several companies, including Accuray, Bill.com, Alvotech, and Estee Lauder, have announced their upcoming quarterly earnings reports, with some providing previews of their financial performance.
A summary of Cardinal Health, Inc.'s fourth-quarter 2026 earnings call provides an overview of the company's financial results and future projections.
Multiple companies, including Greystone Housing Impact, Elbit Systems, and Tencent Music Entertainment, have announced their Q2 2026 earnings previews. Other companies like Geodrill and AG Mortgage Investment Trust have released highlights from their Q2 earnings calls.
Cardinal Health has completed a dual acquisition worth $360 million, aimed at advancing its home care business.
An article analyzes whether Cardinal Health stock (CAH) is outperforming the broader healthcare sector. It likely delves into financial metrics and market trends relevant to the company's performance.
Cardinal Health announced a 1% increase in its quarterly dividend, bringing it to $0.5158 per share.
Cardinal Health, Inc. held its earnings call to summarize its financial performance for the third quarter of 2026.
Cardinal Health has increased its annual profit forecast, citing strong demand for specialty drugs as a key driver for its projected growth.
Financial analysts are releasing Q1 earnings previews for numerous companies, including Amkor Technology and Bed Bath & Beyond. Additionally, several firms are updating price targets and ratings for companies such as Chipotle, Robinhood, and Block.
Zacks Industry Outlook has highlighted Cardinal Health, Becton, Dickinson and Company, and The Cooper Companies, providing insights into their respective industries.
Cardinal Health (CAH) has announced the appointment of a new chair, following the departure of Gregory Kenny from the position.
An analysis suggests that Cardinal Health could be a strong investment choice for the upcoming period of stagflation.
Wells Fargo has raised its outlook for Cardinal Health (CAH), citing the company's broad business strength as the primary reason for the improved forecast.
BioMarin was initiated with an 'outperform' rating by BMO, with analysts suggesting that concerns about Voxzogo erosion are overstated. Cardinal Health also received a new 'outperform' rating from RBC, citing higher margin services.
Multiple companies, including Pixelworks, Inuvo, and B&G Foods, have reported their Q2 2026 earnings, with some missing revenue or EPS estimates. Others, like Arq and Janus, provided revenue and adjusted EBITDA targets for 2026.
Auburn National, JLL Income Property Trust, First Trust Income Opportunities ETF, and Cardinal Health have each declared their latest quarterly dividends to shareholders.
The article explores Cardinal Health's use of share buybacks as a financial strategy, despite the company operating with thin profit margins.
AdaptHealth has announced its intention to sell its Diabetes Health unit to Cardinal Health in an all-cash transaction valued at $235 million.
Wall Street analysts have provided their target price assessments for Cardinal Health stock, indicating their outlook on the company's future performance.
Strong third-quarter earnings for Cardinal Health indicate a potential increase in its dividend payout for May.
Cardinal Health's stock is experiencing a significant decline following the release of mixed financial results, prompting analysts to reassess their investment strategies for the company.
A range of companies, including Landmark Bancorp, The Cheesecake Factory, and Mattel, have announced their latest quarterly financial results, detailing their earnings per share and revenue figures.
The earnings transcript for Cardinal Health's first quarter of 2025 has been made available.
Evercore ISI has slightly reduced its target for Cardinal Health (CAH) while still maintaining a bullish rating on the stock.
Cardinal Health (CAH) has emerged as a significant contributor, driven by strong performance in its pharmaceutical segment and successful margin expansion initiatives.
An analysis suggests that Cardinal Health could be a strong investment choice for the upcoming period of stagflation.
Cardinal Health reported strong earnings that surpassed expectations, though the financial results are said to conceal a more complex story regarding the company's performance.
Analysts are lifting price targets on Cardinal Health following the company's issuance of strong profit guidance, despite the quarter not being entirely clean.
Cardinal Health's stock saw an increase following a strong fiscal 2027 earnings per share outlook and a better-than-expected performance in its fourth-quarter bottom line.
Cardinal Health announced two strategic tuck-in acquisitions, aiming to further expand one of the fastest-growing segments of its business.
Jim Cramer has offered his latest opinions on various stocks, including recommendations for AST SpaceMobile and Moderna, and commentary on companies like Dell, Micron, and Walmart. He also shared his views on the gold market and specific companies like Agnico Eagle and NextEra.
Cardinal Health surpassed its first-quarter profit estimates, leading analysts to increase the company's price target by $4.
A range of companies, including Exponent, Trupanion, Illumina, and Roblox, have announced their financial forecasts for 2026, detailing projected revenues, EPS, and EBITDA margins. Several other companies also reported their latest quarterly or fiscal year results.
Cardinal Health reported a revenue miss that has cast a shadow over its otherwise raised annual profit forecast, indicating mixed financial performance.
William Blair has initiated coverage on pharmaceutical distributor Cardinal Health, assigning it an "Outperform" rating and questioning if the company is a "stealth compounder."
Analysts and investors are looking ahead to Cardinal Health's upcoming earnings report, with previews outlining key areas of focus and expectations.
Jim Cramer has issued a strong recommendation for investors to aggressively purchase shares of Cardinal Health, signaling high confidence in the stock.
Cardinal Health (CAH) experienced a surge in its stock value, attributed to an improved specialty mix within its pharmaceutical segment, as reported by multiple sources.